The impact of CYP allelic variation on antidepressant metabolism: a review

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2007-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1517/17425255.3.1.21PMID 17269892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

  2009cited by this paper
• Coffee, CYP1A2 genotype, and risk of myocardial infarction.

  2006cited by this paper
• Tolerability and safety of fluvoxamine and other antidepressants

  2006cited by this paper
• Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

  2006cited by this paper
• Researchers draft guidelines for clinical use of pharmacogenomics.

  2006cited by this paper
• Monoamine oxidase A gene promoter variation and rearing experience influences aggressive behavior in rhesus monkeys.

  2005cited by this paper
• Steady-state pharmacokinetics of bupropion SR in juvenile patients.

  2005cited by this paper
• Sequence analysis of the serotonin transporter and associations with antidepressant response.

  2005cited by this paper
• Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers.

  2005cited by this paper
• SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY

  2005cited by this paper
• Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders.

  2004cited by this paper
• Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

  2004cited by this paper
• Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.

  2004cited by this paper
• Pharmacogenetics of psychotropic drug response.

  2004cited by this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cited by this paper
• Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics

  2004cited by this paper
• Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

  2004cited by this paper
• Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population

  2003cited by this paper
• Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans

  2003cited by this paper
• Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.

  2003cited by this paper
• Correlation of Cytochrome P450 (CYP) 1A2 Activity Using Caffeine Phenotyping and Olanzapine Disposition in Healthy Volunteers

  2003cited by this paper
• Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.

  2003cited by this paper
• Metabolic drug interactions with new psychotropic agents

  2003cited by this paper
• Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.

  2003cited by this paper
• Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

  2003cited by this paper
• Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

  2003cited by this paper
• The Enzyme Reference: A Comprehensive Guidebook to Enzyme Nomenclature, Reactions, and Methods

  2002cited by this paper
• New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.

  2002cited by this paper
• Identification and functional characterization of new potentially defective alleles of human CYP2C19.

  2002cited by this paper
• The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

  2002cited by this paper
• Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

  2002cited by this paper
• Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.

  2001cited by this paper
• Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers

  2001cited by this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cited by this paper
• Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies

  2001cited by this paper
• (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes.

  2000cited by this paper
• CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

  2000cited by this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cited by this paper
• Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.

  2000cited by this paper
• Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine

  2000cited by this paper
• The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

  2000cited by this paper
• Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.

  2000cited by this paper
• Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

  2000cited by this paper
• In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.

  2000cited by this paper
• Human cytochromes mediating sertraline biotransformation: seeking attribution.

  1999cited by this paper
• Nortriptyline E‐10‐Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme‐Inducing Drugs

  1999cited by this paper
• The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.

  1999cited by this paper
• Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

  1999cited by this paper
• Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes.

  1999cited by this paper
• Metabolic Polymorphisms and Susceptibility to Cancer

  1999cited by this paper
• O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants

  1999cited by this paper
• Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.

  1999cited by this paper
• Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes.

  1999cited by this paper
• New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine

  1998cited by this paper
• Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4

  1998cited by this paper
• Wir sind für Sie nah – Ebewe

  1998cited by this paper
• Metabolism of the Newer Antidepressants

  1998cited by this paper
• Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources.

  1998cited by this paper
• Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state

  1997cited by this paper
• Clinical Pharmacokinetics of Nefazodone

  1997cited by this paper
• Pharmacogenetics of antidepressants: clinical aspects

  1997cited by this paper
• In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans

  1997cited by this paper
• Bupropion plasma levels and CYP2D6 phenotype.

  1996cited by this paper
• The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

  1996cited by this paper
• Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.

  1996cited by this paper
• Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.

  1995cited by this paper
• Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations.

  1995cited by this paper
• Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.

  1994cited by this paper
• Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

  1993cited by this paper
• Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver.

  1993cited by this paper
• The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

  1989cited by this paper
• Metabolism and kinetics of bupropion.

  1983cited by this paper

• Test-retest repeatability of the multiple sleep latency test in non-cataleptic hypersomnolence disorders.

  2026cites this paper
• Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

  2021cites this paper
• CYP2D6, its genetic polymorphism and the brain

  2021cites this paper
• Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.

  2019cites this paper
• Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints.

  2019cites this paper
• Pharmacogenetic clinical decision support for psychiatric hospitalization: Design of the CYP-GUIDES randomized controlled trial.

  2019cites this paper
• The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.

  2018cites this paper
• Practical interpretation of CYP2D6 haplotypes: Comparison and integration of automated and expert calling.

  2016cites this paper
• Psychopharmacogenomics in Pediatric Psychiatry with a Focus on Cytochrome P450 Testing

  2016cites this paper
• Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.

  2015cites this paper
• The current and potential impact of genetics and genomics on neuropsychopharmacology.

  2015cites this paper
• An observational study of Venlafaxine and CYP2D6 in clinical practice.

  2014cites this paper
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

  2013cites this paper
• Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.

  2013cites this paper
• From the lab to the prescription pad: genetics, CYP450 analysis, and medication response.

  2013cites this paper
• Comprehensive Education-Based Mental Health Services for Students Diagnosed on the Autism Spectrum

  2013cites this paper
• Clinical Handbook for the Management of Mood Disorders

  2013cites this paper
• Frequency of Undetected CYP2D6 Hybrid Genes in Clinical Samples: Impact on Phenotype Prediction

  2012cites this paper
• Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

  2012cites this paper
• Psychiatric pharmacogenomics in pediatric psychopharmacology.

  2012cites this paper
• Pharmacogenomics and personalized medicine in neuropsychiatry.

  2012cites this paper
• Genetics and personalized medicine in antidepressant treatment.

  2012cites this paper
• Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.

  2011cites this paper
• Interpreting and Applying CYP450 Genomic Test Results to Psychotropic Medications

  2011cites this paper
• Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

  2011cites this paper
• Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing

  2011cites this paper
• Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.

  2011cites this paper
• Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

  2011cites this paper
• CYP2D6: novel genomic structures and alleles

  2009cites this paper
• Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders

  2009cites this paper
• DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping

  2009cites this paper
• Pharmacogenetics of anxiolytic drugs

  2009cites this paper
• Pharmacogenomic perspectives on the management of mood disorders

  2009cites this paper
• Secondary use of genetic information in research benefits, problems, and potential approaches

  2009cites this paper
• Pharmacogenomics: the promise of personalized medicine for CNS disorders.

  2009cites this paper
• Ethical and evidence-based practice in brain injury rehabilitation

  2009cites this paper
• 4. The issues of phychopharmacotherapy in the elderly: ―精神科領域疾患

  2008cites this paper
• Increased carrier prevalence of defi cient CYP 2 C 9 , CYP 2 C 19 and CYP 2 D 6 alleles in depressed patients referred to a tertiary psychiatric hospital

  2008cites this paper
• Modeling gene-by-environment interaction in comorbid depression with alcohol use disorders via an integrated bioinformatics approach

  2008cites this paper
• Pharmacogenetic testing in psychiatry: a review of features and clinical realities.

  2008cites this paper
• Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital.

  2008cites this paper
• The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

  2007cites this paper